EN

Cerba, a pioneer in the field of genetics

Cerba now responds to all requests for cytogenetic and molecular genetic tests for a large number of clinical indications:
-in prenatal (ultrasound warning signs, developmental abnormalities, etc.), 

-in pediatrics (developmental abnormalities, intellectual deficiency, malformation syndrome, growth disorders, etc.) 

-or in the case of pathologies for which a genetic origin is suspected in most medical specialties (neurology, gynecology, cardiology, hematology, nephrology, dermatology, etc.)

Explore our catalog Télécharger
background
  • Icon_Biologiste bleu
    9

    geneticists

  • Icon_ADN bleu
    25 000

    karyotypes per year

  • Icon_Livre bleu
    30%

    of NIPT tests in France are performed by Cerba

Centralized analyses for comprehensive and rapid support

Search for chromosomal abnormalities, exome or gene panel analysis, etc.: all tests are carried out at the single Frépillon site, allowing several tests to be carried out quickly from the same sample. Our expert geneticists are present and available to advise and guide the tests to be carried out based on the patient's clinical signs and personal and family medical history.

Access our genetics catalog

Our activity is centralized on a single platform. This means we can perform all tests from a single sample, and quickly add additional tests if required, even in other disciplines.

Pascale Kleinfinger

Geneticist

A leading team in genetics

Our molecular genetics and cytogenetics activity relies on an experienced team of physicians or pharmacist-biologists and scientists, supporting clinicians in prescribing tests and interpreting results. 

Recognized specialists in their field, our expert geneticists are members of learned societies (ANPGM, SFMPP for molecular genetics and ACLF for cytogenetics), involved in numerous clinical trials with public (Dijon University Hospital, AP-HP...) and private partners, regularly called upon by the Health Authorities (Agence de Biomédecine, HAS...) and are accredited for pre- and postnatal genetics activity.

We're here to help you choose the most pertinent genetic test based on your patient's clinical signs, personal and family medical history and other tests already performed.

Anne Legrand

Geneticist

An arsenal of techniques to meet the challenges of genetics

Cerba has a very large number of techniques to meet the challenges of diagnosing genetic diseases: FISH (Fluorescence in situ hybridization), conventional cytogenetics (karyotype), ACPA (Chromosomal Analysis by DNA Chip), NIPS (non-invasive prenatal screening), OGM (optical genome mapping), real-time PCR, digital PCR, Sanger sequencing, high-throughput or next-generation sequencing (NGS) for the analysis of the complete exome or gene panels (Aviti). The techniques are mastered by highly qualified teams, making it possible to process large volumes while maintaining the highest level of quality for these examinations.

Discover our genetic tests

Constant innovation in the service of diagnosis

As a pioneer, Cerba is constantly investing in new technologies. Since 2023, we have had two Aviti high-throughput sequencers, offering a quality score (Q40) that has been unmatched until now.

In 2023, Cerba also integrated Optical Genome Mapping (OGM), an innovative technology based on the imaging of high molecular weight DNA molecules. It allows a genome-wide analysis of balanced or unbalanced chromosomal variants with a resolution 10,000 times higher than that of karyotype.

Discover our medical innovations

A Reference Medical Biology Laboratory

As proof of its level of excellence, Cerba is recognized as a LBMR (Reference Medical Biology Laboratory) in France for, on the one hand, chromosomal anomalies and on the other hand for certain fetal pathologies (aneuploidies including trisomies 21, 18 and 13, X-linked genetic diseases, congenital adrenal hyperplasia, sexual ambiguity, hemolytic disease of the newborn by fetomaternal alloimmunization, achondroplasia and hypochondroplasia).

Pharmacogenetics at Cerba

Pharmacogenetics, a cutting-edge discipline in medical biology, studies how genetic variations influence treatment responses. It allows for personalized therapies by adjusting dosages or by selecting specific medications based on the patient’s genetic profile. This approach promotes more effective medicine and reduces sides effects and therapeutic wandering, which is particularly significant in psychiatry, for example. 

A first panel of pharmacogenetic analyses has recently been developed at the Cerba laboratory to study the impact of certain genetic polymorphisms on the response to treatment and the pharmacokinetic profile of antidepressants. 

Our expert biologists are certified in genetics to perform these pharmacogenetic tests.

 

  • Icon_Loupe bleu
    160 000

    molecular genetic tests per year 

  • Icon_microscope bleu
    + 100%

    NGS activity since 2021

  • Icon_Tube bleu
    10

    NGS sequencers including 2 Aviti

Medical team in Genetics